Not applicableActive Not RecruitingNCT03691064What this trial is testingPost-Authorization Long-Term Safety Study of LUTATHERAWho this might be right forNeuroendocrine Tumors Advanced Accelerator Applications 1,014
Large-scale testing (Phase 3)Study completedNCT06091748What this trial is testingGallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine TumorsWho this might be right forAdvanced Gastroenteropancreatic Neuroendocrine Tumor Jiangsu HengRui Medicine Co., Ltd. 69
Testing effectiveness (Phase 2)WithdrawnNCT04915144What this trial is testing177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETsWho this might be right forNeuroendocrine TumorsCarcinoid TumorPulmonary Carcinoid Tumor+4 more British Columbia Cancer Agency
Not applicableStudy completedNCT04946305What this trial is testingA Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in KoreaWho this might be right forSomatostatin Receptor-positive GEP-NET Novartis Pharmaceuticals 89
Testing effectiveness (Phase 2)Looking for participantsNCT05048901What this trial is testingCabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine TumorsWho this might be right forNeuroendocrine Tumors,Gastroenteropancreatic National Health Research Institutes, Taiwan 49
Early research (Phase 1)Looking for participantsNCT07006727What this trial is testingPhase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid TumorsWho this might be right forSmall Cell Lung CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungNeuroendocrine Prostate Cancer+8 more Novartis Pharmaceuticals 116
Not applicableLooking for participantsNCT06155318What this trial is testing68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine TumoursWho this might be right forGastroenteropancreatic Neuroendocrine Tumor IRCCS San Raffaele 300
Early research (Phase 1)Ended earlyNCT05364944What this trial is testingAssess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)Who this might be right forAcromegalyGEP-NET Debiopharm International SA 19
Very early researchActive Not RecruitingNCT04544098What this trial is testingLutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the LiverWho this might be right forNeuroendocrine TumorsLiver-Dominant Metastatic Pancreatic Neuroendocrine Tumors Memorial Sloan Kettering Cancer Center 10
Large-scale testing (Phase 3)Looking for participantsNCT05477576What this trial is testingStudy of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyWho this might be right forGEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor Disease+4 more RayzeBio, Inc. 338
Testing effectiveness (Phase 2)UnknownNCT04427787What this trial is testingA Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NETWho this might be right forMetastatic Well Differentiated Neuroendocrine NeoplasmNeuroendocrine Tumors Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 69
Testing effectiveness (Phase 2)Looking for participantsNCT07278479What this trial is testingStudy of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid TumorsWho this might be right forLarge Cell Neuroendocrine CarcinomaLarge Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)+4 more Molecular Partners AG 138
Testing effectiveness (Phase 2)Looking for participantsNCT05636618What this trial is testingTargeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive TumorsWho this might be right forNeuroendocrine Tumors UnresectableNeuroendocrine Tumor MetastaticGastroenteropancreatic Neuroendocrine Tumor+4 more Perspective Therapeutics 300
Testing effectiveness (Phase 2)Ended earlyNCT05987176What this trial is testingComparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver MetastasesWho this might be right forNeuroendocrine Tumor G1 (NET G1)/CarcinoidNeuroendocrine Tumor Grade 2Neuroendocrine Tumors+3 more Imperial College London 1
Not applicableUnknownNCT05268952What this trial is testingEvaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)Who this might be right forNeuroendocrine Tumors University Hospital, Antwerp 100
Large-scale testing (Phase 3)Active Not RecruitingNCT04919226What this trial is testingLutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSEWho this might be right forNeuroendocrine Tumors ITM Solucin GmbH 259
Not applicableStudy completedNCT02948946What this trial is testingClinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine TumorsWho this might be right forGastroenteropancreatic Neuroendocrine TumorLung Neuroendocrine Neoplasm H. Lee Moffitt Cancer Center and Research Institute 105
Large-scale testing (Phase 3)Looking for participantsNCT06937905What this trial is testingTarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)Who this might be right forNeuroendocrine Carcinoma Intergroupe Francophone de Cancerologie Thoracique 129
Testing effectiveness (Phase 2)Study completedNCT02248012What this trial is testingEverolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)Who this might be right forNeuroendocrine Carcinoma Haukeland University Hospital 38
Not applicableStudy completedNCT07653126What this trial is testingPeptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in GermanyWho this might be right forGastro-enteropancreatic Neuroendocrine Tumor Novartis Pharmaceuticals 117